Last updated on January 2017

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE


Brief description of study

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE

Detailed Study Description

Receive Ubrogepant or placebo for treatment of migraines

Clinical Study Identifier: TX147253

Contact Investigators or Research Sites near you

Start Over

Herenia Sanchez-Lacayo, CRC

Clinical Research of South Florida
Coral Gables, FL USA
  Connect »